International Psoriasis Council

Advancing Knowledge. Improving Care.

Axel

Svedbom

,

MSc, PhD

Researcher
Karolinska Institutet
Stockholm
,
Sweden
Dr. Axel Svedbom, MSc, PhD, is a Researcher at the Karolinska Institutet, Stockholm, Sweden. He completed his PhD in register-based research in psoriasis in 2021. He is widely published in Dermatology, with numerous abstracts and papers published in the JAMA Dermatology, the Journal of the American Academy of Dermatology (JAAD), the Journal of Investigative Dermatology (JID), and the Journal of the European Academy of Dermatology (JEADV). Dr. Svedbom’s research focuses on integrating data from the lab, patients, medical records, and registers to predict the long-term development of psoriasis and understand the mechanisms underlying the associations between psoriasis and other diseases such as cardiovascular disease, depression, and inflammatory bowel disease. To this end, he works with four distinct and unique cohorts. He has received grants from the National Psoriasis Foundation (NPF), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and the Swedish Psoriasis Foundation.
Last Updated:
08/01/2023

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026